All PlansCoverageMedium impact

Newsletter Vol. 24, No.13

Q: Who is affected by this change?

This affects New Jersey Medicaid Family Medicine, Internal Medicine, Psychiatry, Pain Management, Addiction Medicine providers in NJ on All Plans plans.

New Jersey Medicaid·NJ · Family Medicine, Internal Medicine, Psychiatry +2 more·Provider Notice

Effective date

Not stated

We identified it

Jun 20, 2026

Days to comply

—

Summary

New buprenorphine prescribing and billing guidelines have been issued, likely affecting medication-assisted treatment (MAT) services. This may impact prior authorization requirements, coverage criteria, or billing procedures for buprenorphine products used in opioid use disorder treatment.

Action Required

Action needed

Immediately: Review Newsletter Vol. 24, No.13 for complete buprenorphine guidelines at https://www.njmmis.com/documentDownload.aspx?document=24-13.pdf. Billing team should identify any changes to prior authorization requirements, coverage criteria, or billing procedures for buprenorphine products and update workflows accordingly.

Related policy hubs

New Jersey Medicaid policies NJ policy changes Family Medicine Internal Medicine Psychiatry Pain Management Addiction Medicine